Letter to the Editor
On the article “Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window”
Abstract
French and Hamilton reviewed our publication entitled “Blockade of protease-activated receptor-4 provides robust antithrombotic activity with low bleeding” (1) positively and provided ideas and insights for future research on the drug target protease-activated receptor-4 (PAR4) (2). We have a few remarks addressing the concerns raised by French and Hamilton.
